Effect of Co-Administration of Telmisartan with a Luteolin in Dexamethasone Induced Insulin Resistance in Mice

Author: Yogesh S. Ahire, Subrato Kundu and Vinod A Bairagi

Download PDF

Abstract

Current investigation was planned to evaluate co-administering low and high doses of telmisartan with luteolin in mice with insulin resistance caused by dexamethasone. The grouping of mice into eight different groups was done randomly (n=6): DC, NC, TEL-I, TEL-II, LUT, PIO, TL-I, and TL-II. From 1st day to 22nd day, all groups of mice were injected dexamethasone with at a dosage of 1 mg per kg per day and their respective drugs from day 8 to day 22, except NC group. Glucose as well as triglyceride levels were assessed on 1st, 7th and 22nd days. Mice were euthanized and their livers separated to determine content of antioxidant enzymes and glycogen, while hemidiaphragm was isolated for estimation of glucose uptake. Combination groups TL-I and TL-II showed a prominent increase in utilization of glucose uptake and % change in body weight when compared to DC, TEL-I, TEL-II, and LUT groups. TL-II group demonstrated a remarkable reduction in levels of glucose as well as triglycerides when matched to DC, TEL-I, TEL-II, and LUT groups. Furthermore, TL-I and TL-II showed a remarkable rise in liver antioxidants as well as glycogen content with LPO concentration was reduced significantly in correlation to DC, LUT, TEL-I, and TEL-II groups. From present investigation, concludes that combination of telmisartan with luteolin exhibited synergistic effects in normalizing all estimated parameters compared to individual treated groups in experimental animals with dexamethasone-induced insulin resistance.

Keywords

Telmisartan, Dexamethasone, Insulin resistance, Type 2 diabetes, Luteolin

Conclusion

From current investigation, we determined, combination of telmisartan with luteolin demonstrated significant as well as ensuring results in dexamethasone-induced diabetes of type 2 treatment, compared to individual treatment groups. Both telmisartan and luteolin exhibited antidiabetic, antihyperlipidemic, and antioxidant potential, and their combination exhibited a synergistic effect in relation to various biochemical, morphological parameters. Further research is needed to evaluate the potential of the combination of telmisartan with luteolin on the long-term complications of type 2 diabetes preclinically.

References

-

How to cite this article

Yogesh S. Ahire, Subrato Kundu and Vinod A Bairagi (2023). Effect of Co-Administration of Telmisartan with a Luteolin in Dexamethasone Induced Insulin Resistance in Mice. Biological Forum – An International Journal, 15(5): 1642-1654.